Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onxeo Adjusts Direction With Acquisition Of DNA-Repair Interference Platform

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm that was focused on technology to reformulate old drugs gains platform for novel drugs that will induce cell death in orphan oncology indications.

You may also be interested in...



US Drug Shortages In COVID-19 Era: A Domestic Problem With Domestic Solutions

Rather than rail at China, senators explored causes and corrective actions for drug shortages that are closer to home.

The COVID-19 Effect: Medicare Part B Oncology Drug Claims Down 40% Through April

Study commissioned by the PhRMA underscores concerns about how the coronavirus has disrupted use of physician-administered drugs.

NCI Is Being 'Flexible' With COVID-19 Clinical Trial Protocols

At ASCO symposium on cancer care during the pandemic, NCI Director Ned Sharpless notes trial accrual at NCI's National Clinical Trials Network dropped by half in March and April.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

GB140216

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel